Abstract
Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.